Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Will psychedelics be ‘a revolution in psychiatry’?
Mind-altering drugs such as psilocybin and MDMA could transform the treatment paradigm for mental health disorders, says neuroscientist David Nutt. But trial design considerations, regulatory hurdles and economics still pose problems for psychedelic-assisted therapies.
When David Nutt started working as a psychiatrist and neuropsycho-pharmacologist in the 1970s, the glow of the first psychedelic era was already fading. Despite evidence that LSD, psilocybin and MDMA might work wonders in mental health, the perceived dangers of mind-altering agents — and their use by counterculture groups — had spooked the medical establishment. When governments made these compounds illegal, research into their potential therapeutic uses ground to a near halt.